TY - JOUR
T1 - SARS-CoV-2-specific immune responses converge in kidney disease patients and controls with hybrid immunity
AU - Aguilar-Bretones, Muriel
AU - den Hartog, Yvette
AU - van Dijk, Laura L.A.
AU - Malahe, S. Reshwan K.
AU - Dieterich, Marjolein
AU - Mora, Héctor Tejeda
AU - Mueller, Yvonne M.
AU - Koopmans, Marion P.G.
AU - Reinders, Marlies E.J.
AU - Baan, Carla C.
AU - van Nierop, Gijsbert P.
AU - de Vries, Rory D.
AU - Abrahams, Alferso C.
AU - Baas, Marije C.
AU - Hemmelder, Marc H.
AU - Bouwmans, Pim
AU - ten Dam, Marc A.G.J.
AU - Gommers, Lennert
AU - RECOVAC Consortium
N1 - Funding Information:
The authors acknowledge financial support by the European Union\u2019s Horizon 2020 research and innovation program under grant agreements no. 874735 (VEO) and no. 101003589 (RECoVER) and the Dutch Research Council (NWO) project no. 109986 (One Health Pact). The Netherlands Organization for Health Research and Development (ZonMw), project number: 10430072010002 (RECOVAC) and 10430072110008 (OVERARCHING). This study was also supported by the Dutch Kidney Foundation (project 21OP + 036 and CP1801). Organizations had no role in the design of the study, data interpretation, writing of the manuscript, nor in the decision to submit the manuscript. We would like to thank the RECOVAC collaborators: Alferso C. Abrahams, MD, PhD, Department of Nephrology and Hypertension, University Medical Center Utrecht, Utrecht, the Netherlands; Marije C. Baas, MD, PhD, Department of Nephrology, Radboud University Medical Center, Radboud Institute for Health Sciences, Nijmegen, the Netherlands; Marc H. Hemmelder, MD, PhD, and Pim Bouwmans, MD, Division of Nephrology, Department of Internal Medicine, Maastricht University Medical Center and CARIM School for Cardiovascular Disease, University of Maastricht, Maastricht, the Netherlands; Marc A.G.J. ten Dam, MD, PhD, Dutch Registry RENINE, Nefrovisie, Utrecht, the Netherlands; Lennert Gommers, BSc, Department of Viroscience, Erasmus Medical Center, Rotterdam, the Netherlands; and Aiko P.J. de Vries, MD, PhD, Department of Nephrology, Leiden University Medical Center, Leiden, the Netherlands. Furthermore, we would like to thank Marit J. van Gils, PhD, Amsterdam UMC, the Netherlands for technical advice on B-cell analysis.
Funding Information:
The authors acknowledge financial support by the European Union\u2019s Horizon 2020 research and innovation program under grant agreements no. 874735 (VEO) and no. 101003589 (RECoVER) and the Dutch Research Council (NWO) project no. 109986 (One Health Pact). The Netherlands Organization for Health Research and Development (ZonMw), project number: 10430072010002 (RECOVAC) and 10430072110008 (OVERARCHING). This study was also supported by the Dutch Kidney Foundation (project 21OP\u2009+\u2009036 and CP1801). Organizations had no role in the design of the study, data interpretation, writing of the manuscript, nor in the decision to submit the manuscript. We would like to thank the RECOVAC collaborators: Alferso C. Abrahams, MD, PhD, Department of Nephrology and Hypertension, University Medical Center Utrecht, Utrecht, the Netherlands; Marije C. Baas, MD, PhD, Department of Nephrology, Radboud University Medical Center, Radboud Institute for Health Sciences, Nijmegen, the Netherlands; Marc H. Hemmelder, MD, PhD, and Pim Bouwmans, MD, Division of Nephrology, Department of Internal Medicine, Maastricht University Medical Center and CARIM School for Cardiovascular Disease, University of Maastricht, Maastricht, the Netherlands; Marc A.G.J. ten Dam, MD, PhD, Dutch Registry RENINE, Nefrovisie, Utrecht, the Netherlands; Lennert Gommers, BSc, Department of Viroscience, Erasmus Medical Center, Rotterdam, the Netherlands; and Aiko P.J. de Vries, MD, PhD, Department of Nephrology, Leiden University Medical Center, Leiden, the Netherlands. Furthermore, we would like to thank Marit J. van Gils, PhD, Amsterdam UMC, the Netherlands for technical advice on B-cell analysis.
Publisher Copyright:
© The Author(s) 2024.
PY - 2024/12/1
Y1 - 2024/12/1
N2 - Healthy individuals with hybrid immunity, due to a SARS-CoV-2 infection prior to first vaccination, have stronger immune responses compared to those who were exclusively vaccinated. However, little is known about the characteristics of antibody, B- and T-cell responses in kidney disease patients with hybrid immunity. Here, we explored differences between kidney disease patients and controls with hybrid immunity after asymptomatic or mild coronavirus disease-2019 (COVID-19). We studied the kinetics, magnitude, breadth and phenotype of SARS-CoV-2-specific immune responses against primary mRNA-1273 vaccination in patients with chronic kidney disease or on dialysis, kidney transplant recipients, and controls with hybrid immunity. Although vaccination alone is less immunogenic in kidney disease patients, mRNA-1273 induced a robust immune response in patients with prior SARS-CoV-2 infection. In contrast, kidney disease patients with hybrid immunity develop SARS-CoV-2 antibody, B- and T-cell responses that are equally strong or stronger than controls. Phenotypic analysis showed that Spike (S)-specific B-cells varied between groups in lymph node-homing and memory phenotypes, yet S-specific T-cell responses were phenotypically consistent across groups. The heterogeneity amongst immune responses in hybrid immune kidney patients warrants further studies in larger cohorts to unravel markers of long-term protection that can be used for the design of targeted vaccine regimens.
AB - Healthy individuals with hybrid immunity, due to a SARS-CoV-2 infection prior to first vaccination, have stronger immune responses compared to those who were exclusively vaccinated. However, little is known about the characteristics of antibody, B- and T-cell responses in kidney disease patients with hybrid immunity. Here, we explored differences between kidney disease patients and controls with hybrid immunity after asymptomatic or mild coronavirus disease-2019 (COVID-19). We studied the kinetics, magnitude, breadth and phenotype of SARS-CoV-2-specific immune responses against primary mRNA-1273 vaccination in patients with chronic kidney disease or on dialysis, kidney transplant recipients, and controls with hybrid immunity. Although vaccination alone is less immunogenic in kidney disease patients, mRNA-1273 induced a robust immune response in patients with prior SARS-CoV-2 infection. In contrast, kidney disease patients with hybrid immunity develop SARS-CoV-2 antibody, B- and T-cell responses that are equally strong or stronger than controls. Phenotypic analysis showed that Spike (S)-specific B-cells varied between groups in lymph node-homing and memory phenotypes, yet S-specific T-cell responses were phenotypically consistent across groups. The heterogeneity amongst immune responses in hybrid immune kidney patients warrants further studies in larger cohorts to unravel markers of long-term protection that can be used for the design of targeted vaccine regimens.
U2 - 10.1038/s41541-024-00886-0
DO - 10.1038/s41541-024-00886-0
M3 - Article
VL - 9
JO - npj Vaccines
JF - npj Vaccines
IS - 1
M1 - 93
ER -